Preclinical data underpinning this trial demonstrated that Ad5f35-engineered CAR-Ms not only directly phagocytose HER2+ tumor cells but also remodel immunosuppressive microenvironments via pro-inflammatory cytokine secretion, thereby enhanad5cing T cell infiltration. This evidence concerns the gene ERBB2 and neoplasm.